Literature DB >> 25384099

Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders.

Eoin P Flanagan1, Brian G Weinshenker1, Karl N Krecke2, Vanda A Lennon3, Claudia F Lucchinetti1, Andrew McKeon4, Dean M Wingerchuk5, Elizabeth A Shuster6, Yujuan Jiao7, Erika S Horta7, Sean J Pittock4.   

Abstract

IMPORTANCE: Short transverse myelitis (STM; <3 vertebral segments) is considered noncharacteristic of neuromyelitis optica (NMO) spectrum disorders (NMOSDs). Nonappreciation of the potential for STM to occur in NMOSD may lead to increased disability from delay in diagnosis and appropriate treatment.
OBJECTIVES: To determine the frequency of short lesions at the initial myelitis manifestation of NMOSD and to compare the demographic, clinical, and radiological characteristics of aquaporin-4-IgG (AQP4-IgG) seropositive and seronegative STM. DESIGN, SETTING, AND PARTICIPANTS: We reviewed the records and images of patients at the Mayo Clinic who were identified as AQP4-IgG positive from 1996 to 2014. Inclusion criteria were first STM episode, magnetic resonance imaging performed 90 days or less from symptom onset, spinal cord T2-hyperintense lesion less than 3 vertebral segments, AQP4-IgG seropositivity, and a final diagnosis of NMO or NMOSD. Patients with an initial longitudinally extensive transverse myelitis were excluded (n = 151). Patients with STM who were seronegative for AQP4-IgG among an Olmsted County population-based cohort of inflammatory demyelinating disorders of the central nervous system were used as a control group. MAIN OUTCOMES AND MEASURES: Delay to diagnosis in months, clinical and radiological characteristics, and disability measured by ambulatory status.
RESULTS: Twenty-five patients who were AQP4-IgG seropositive with an initial STM represented 14% of initial myelitis episodes among patients with NMOSD. The STM episode was defined as the first manifestation of NMOSD in 10 patients (40%) preceded by optic neuritis in 13 patients (52%) and preceded by a nausea and vomiting episode in 2 patients (8%). In comparison with the excluded patients with NMOSD who had an initial longitudinally extensive transverse myelitis, delay to diagnosis/treatment was greater when initial lesions were short (P = .02). In AQP4-IgG-positive STM cases, subsequent myelitis episodes were longitudinally extensive in 92%. Attributes more common in patients with AQP4-IgG-positive STM than in 27 population-based patients with AQP4-IgG-negative STM included the following: nonwhite race/ethnicity; tonic spasms; coexisting autoimmunity; magnetic resonance imaging (central cord lesions, T1 hypointensity, and a brain inconsistent with multiple sclerosis); and cerebrospinal fluid (oligoclonal bands lacking). CONCLUSIONS AND RELEVANCE: Short transverse myelitis is not uncommon in NMOSD and, when it is present, delays diagnosis and treatment. Clinical and radiological characteristics identified in this study may help select patients with STM who are at the highest risk for an NMOSD. Short transverse myelitis does not exclude consideration of AQP4-IgG testing or NMOSD diagnosis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25384099      PMCID: PMC4552048          DOI: 10.1001/jamaneurol.2014.2137

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  20 in total

1.  A benign form of neuromyelitis optica: does it exist?

Authors:  Nicolas Collongues; Philippe Cabre; Romain Marignier; Hèléne Zéphir; Caroline Papeix; Bertrand Audoin; Christine Lebrun-Frenay; Jean Pelletier; Bertrand Fontaine; Patrick Vermersch; Christian Confavreux; Jérôme de Seze
Journal:  Arch Neurol       Date:  2011-07

2.  Neuromyelitis optica IgG status in acute partial transverse myelitis.

Authors:  Thomas F Scott; Salima L Kassab; Sean J Pittock
Journal:  Arch Neurol       Date:  2006-10

3.  Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis.

Authors:  Brian G Weinshenker; Dean M Wingerchuk; Sandra Vukusic; Linda Linbo; Sean J Pittock; Claudia F Lucchinetti; Vanda A Lennon
Journal:  Ann Neurol       Date:  2006-03       Impact factor: 10.422

4.  A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.

Authors:  Vanda A Lennon; Dean M Wingerchuk; Thomas J Kryzer; Sean J Pittock; Claudia F Lucchinetti; Kazuo Fujihara; Ichiro Nakashima; Brian G Weinshenker
Journal:  Lancet       Date:  2004 Dec 11-17       Impact factor: 79.321

5.  Revised diagnostic criteria for neuromyelitis optica.

Authors:  D M Wingerchuk; V A Lennon; S J Pittock; C F Lucchinetti; B G Weinshenker
Journal:  Neurology       Date:  2006-05-23       Impact factor: 9.910

Review 6.  Proposed diagnostic criteria and nosology of acute transverse myelitis.

Authors: 
Journal:  Neurology       Date:  2002-08-27       Impact factor: 9.910

7.  Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders.

Authors:  B Banwell; S Tenembaum; V A Lennon; E Ursell; J Kennedy; A Bar-Or; B G Weinshenker; C F Lucchinetti; S J Pittock
Journal:  Neurology       Date:  2007-12-19       Impact factor: 9.910

8.  Neuromyelitis optica-IgG in idiopathic inflammatory demyelinating disorders amongst Hong Kong Chinese.

Authors:  K H Chan; D B Ramsden; Y L Yu; K H H Kwok; A C Y Chu; P W L Ho; J S C Kwan; R Lee; E Lim; M H W Kung; S L Ho
Journal:  Eur J Neurol       Date:  2009-03       Impact factor: 6.089

9.  Aquaporin 4 IgG serostatus and outcome in recurrent longitudinally extensive transverse myelitis.

Authors:  Yujuan Jiao; James P Fryer; Vanda A Lennon; Andrew McKeon; Sarah M Jenkins; Carin Y Smith; Amy M L Quek; Brian G Weinshenker; Dean M Wingerchuk; Elizabeth A Shuster; Claudia F Lucchinetti; Sean J Pittock
Journal:  JAMA Neurol       Date:  2014-01       Impact factor: 18.302

10.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Authors:  Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

View more
  51 in total

1.  Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody.

Authors:  Divyanshu Dubey; Sean J Pittock; Karl N Krecke; Padraig P Morris; Elia Sechi; Nicholas L Zalewski; Brian G Weinshenker; Eslam Shosha; Claudia F Lucchinetti; James P Fryer; A Sebastian Lopez-Chiriboga; John C Chen; Jiraporn Jitprapaikulsan; Andrew McKeon; Avi Gadoth; B Mark Keegan; Jan-Mendelt Tillema; Elie Naddaf; Marc C Patterson; Kevin Messacar; Kenneth L Tyler; Eoin P Flanagan
Journal:  JAMA Neurol       Date:  2019-03-01       Impact factor: 18.302

Review 2.  Common and Rare Manifestations of Neuromyelitis Optica Spectrum Disorder.

Authors:  Dominique Rosales; Ilya Kister
Journal:  Curr Allergy Asthma Rep       Date:  2016-06       Impact factor: 4.806

Review 3.  Spinal cord MRI in multiple sclerosis--diagnostic, prognostic and clinical value.

Authors:  Hugh Kearney; David H Miller; Olga Ciccarelli
Journal:  Nat Rev Neurol       Date:  2015-05-26       Impact factor: 42.937

4.  Severe aquaporin-4 IgG-positive neuromyelitis optica spectrum disorder with short myelitis lesion and favourable outcome.

Authors:  Gianni Masi; Chiara Cioni; Umberto Arrigucci; Alfonso Cerase; Pasquale Annunziata
Journal:  Neurol Sci       Date:  2015-06-07       Impact factor: 3.307

5.  Asymptomatic myelitis in neuromyelitis optica and autoimmune aquaporin-4 channelopathy.

Authors:  Eoin P Flanagan; Brian G Weinshenker; Karl N Krecke; Sean J Pittock
Journal:  Neurol Clin Pract       Date:  2015-04

6.  Racial differences in neuromyelitis optica spectrum disorder.

Authors:  Su-Hyun Kim; Maureen A Mealy; Michael Levy; Felix Schmidt; Klemens Ruprecht; Friedemann Paul; Marius Ringelstein; Orhan Aktas; Hans-Peter Hartung; Nasrin Asgari; Jessica Li Tsz-Ching; Sasitorn Siritho; Naraporn Prayoonwiwat; Hyun-June Shin; Jae-Won Hyun; Mira Han; Maria Isabel Leite; Jacqueline Palace; Ho Jin Kim
Journal:  Neurology       Date:  2018-10-26       Impact factor: 9.910

Review 7.  Differential Diagnosis of Acute Myelopathies: An Update.

Authors:  M Nichtweiß; S Weidauer
Journal:  Clin Neuroradiol       Date:  2015-06-02       Impact factor: 3.649

Review 8.  Treatment of primary Sjögren syndrome.

Authors:  Alain Saraux; Jacques-Olivier Pers; Valérie Devauchelle-Pensec
Journal:  Nat Rev Rheumatol       Date:  2016-07-14       Impact factor: 20.543

Review 9.  The current role of MRI in differentiating multiple sclerosis from its imaging mimics.

Authors:  Ruth Geraldes; Olga Ciccarelli; Frederik Barkhof; Nicola De Stefano; Christian Enzinger; Massimo Filippi; Monika Hofer; Friedemann Paul; Paolo Preziosa; Alex Rovira; Gabriele C DeLuca; Ludwig Kappos; Tarek Yousry; Franz Fazekas; Jette Frederiksen; Claudio Gasperini; Jaume Sastre-Garriga; Nikos Evangelou; Jacqueline Palace
Journal:  Nat Rev Neurol       Date:  2018-03-09       Impact factor: 42.937

Review 10.  Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders.

Authors:  Ingo Kleiter; Ralf Gold
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.